<DOC>
	<DOC>NCT00062491</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.</brief_summary>
	<brief_title>Study of Karenitecin (BNP1350) to Treat Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Confirmed diagnosis of malignant melanoma Measurable disease Granulocytes ≥1,500/µl, Platelets ≥100,000/µl, Creatinine ≤ULN, Bilirubin ≤1.5 mg/dl, AST ≤2.5 x ULN No prior treatment with other camptothecin drug. ≥ 21 days since completion of prior chemotherapy, ≥6 weeks since prior MitomycinC ECOG Performance Status 01 Negative pregnancy test for female patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>